In our previous work, CD16 expression on NK cells was shown to be decreased in ICU and moderate patients with COVID-19 [43], while in this work, no significant differences in the proportion of CD16+ NKT-like cells were recorded between the COVID-19 patient groups. The gene discussed is FCGR3A; the disease is COVID-19.